As regulators continue to scrutinise compounded GLP-1 products and Health Canada maintains strict controls around unauthorised therapeutic goods, specialist compounders are increasingly looking at how peptide capabilities can support a broader formulation strategy.

That means understanding the wider peptide landscape, identifying appropriate therapeutic opportunities and developing access to GMP peptide APIs that can support specialist formulations where compounding is permitted.

The commercial advantage is diversification.

The peptide market is much bigger than GLP-1

GLP-1 therapies have brought peptides into the mainstream, but peptide therapeutics are hardly a new pharmaceutical concept.

Peptide medicines are already established across areas including endocrinology, metabolic disease, oncology and reproductive health. More than 80 peptide drugs have been approved globally, while hundreds of peptide candidates are currently being investigated across clinical development.

The pipeline is also becoming more sophisticated.

Research is expanding into longer-acting peptides, peptide-drug conjugates, orally administered peptides and combination therapies. Advances in peptide synthesis and formulation are opening opportunities that extend well beyond the familiar injectable GLP-1 model.

For Canadian compound pharmacies, that creates a broader market to monitor.

The opportunity is not necessarily to chase experimental molecules.

It is to identify established or appropriate specialist APIs where a legitimate formulation requirement exists and where Canadian regulations permit compounding.

GLP-1 restrictions make diversification more important

The regulatory environment makes diversification particularly relevant.

Health Canada has taken action against unauthorised GLP-1 products and has repeatedly warned Canadians about purchasing injectable weight-loss products from unregulated sources.

There are also specific restrictions and professional considerations around compounding products that have commercially available alternatives.

This means GLP-1 demand cannot simply be treated as an open commercial opportunity for compound pharmacies.

For a business building a long-term peptide proposition, relying heavily on one category creates unnecessary exposure to regulatory change, product availability and market competition.

Diversification provides another route.

A broader peptide capability allows compounders to assess opportunities across different therapeutic areas rather than building their entire proposition around one highly visible class.

Endocrinology remains a natural peptide market

One of the strongest areas for peptide development beyond GLP-1 remains endocrinology.

Peptide hormones have been part of modern medicine for decades, with established applications involving insulin, parathyroid hormone analogues, growth hormone and reproductive hormones.

The science continues to develop.

Long-acting formulations, modified peptide structures and improved delivery technologies are being investigated to extend therapeutic duration and improve patient convenience.

For compound pharmacies, endocrinology can therefore represent a more mature peptide environment than some of the newer categories attracting attention online.

Where a patient requires a legitimate formulation that differs from an available commercial product, access to suitable APIs can support a specialist compounding service.

Oncology is another area to watch

Peptide science is also playing an increasingly important role in oncology.

Peptides can be engineered to interact selectively with receptors expressed by particular tumour types, creating opportunities for targeted drug delivery and diagnostic imaging.

Peptide receptor radionuclide therapy is already established in certain cancers, while research continues into peptide-drug conjugates designed to deliver active pharmaceutical ingredients more selectively.

The commercial relevance for compound pharmacies is longer term.

Not every emerging oncology peptide will be appropriate for pharmacy compounding.

Many are specialist hospital medicines or investigational products.

But the direction of research demonstrates why compounders should avoid defining the peptide market solely through weight management.

The technology is being applied across a much wider pharmaceutical landscape.

Personalised medicine creates another opening

The broader shift towards personalised medicine also supports the case for specialist formulation.

Canada’s healthcare system is increasingly incorporating precision medicine approaches, particularly in oncology and rare diseases. As treatment becomes more targeted, the requirement for formulations that accommodate individual patient needs can become more complex.

That is where the compounding model can have a role.

A commercially manufactured medicine is designed around a standard patient population.

A compounded formulation can, where legally and clinically appropriate, be adapted to a specific requirement — for example, a particular dosage form, strength or excipient profile.

Peptides are technically demanding APIs, but that same complexity can make specialist formulation capabilities more valuable.

For compound pharmacies, the objective is to develop the capability without overextending the portfolio.

The opportunity is specialist, not speculative

There is a crucial distinction between diversification and speculation.

The emergence of a new peptide on social media does not make it a viable pharmaceutical product.

Compound pharmacies need to assess each API based on its regulatory status, clinical rationale, sourcing options and formulation requirements.

That is particularly important in Canada, where Health Canada continues to intervene against unauthorised peptide products.

A sustainable peptide strategy should therefore focus on pharmaceutical relevance rather than online popularity.

GMP sourcing supports that approach.

Working with qualified manufacturers gives compounders access to APIs produced within controlled pharmaceutical environments and allows them to build their internal processes around defined material specifications.

Better API access supports portfolio agility

A diversified peptide portfolio does not mean holding every possible peptide in inventory.

It means having the sourcing capability to respond when an appropriate requirement appears.

That distinction can significantly reduce inventory risk.

Rather than purchasing large quantities of speculative ingredients, a compound pharmacy can establish relationships with specialist API suppliers and source materials according to genuine formulation demand.

This approach also allows the portfolio to evolve.

If demand emerges in endocrinology, a specialist API can be sourced. If another therapeutic area develops a legitimate compounding requirement, the same sourcing infrastructure can be used to investigate that opportunity.

The value lies in the network.

MedicaPharma works with more than 400 GMP manufacturers, providing pharmaceutical customers with access to specialist and niche APIs through an established international sourcing network.

For Canadian compound pharmacies, that creates a route to a broader range of peptide ingredients without requiring procurement teams to manage multiple international manufacturing relationships themselves.

A diversified portfolio can strengthen the B2B proposition

There is also a commercial benefit to moving beyond a single peptide category.

A compound pharmacy with broader specialist formulation capabilities can potentially serve a wider B2B customer base.

Prescribers treating complex or individualised cases may require formulations that are not readily available commercially. Healthcare businesses may also look for specialist formulation partners with the technical capabilities to handle less conventional dosage requirements.

The more robust the compounder’s API network, the easier it becomes to assess those opportunities.

This does not mean every request should be accepted.

Quite the opposite.

A strong B2B proposition is built on knowing which opportunities fit the business and which do not.

The next peptide opportunity may be less obvious

The biggest peptide story of the past few years has been GLP-1.

The next one may look very different.

It could involve a new delivery technology, a specialist hormone application, targeted therapy or an entirely different therapeutic category.

For compound pharmacies, predicting the exact winner is less important than being prepared to evaluate the opportunity.

That means investing in the fundamentals: specialist formulation expertise, qualified API suppliers and a procurement process capable of sourcing technically demanding ingredients when required.

GMP peptide APIs provide the foundation.

Build beyond the GLP-1 cycle

Canada’s peptide market is becoming more regulated, but that does not mean the opportunity is disappearing.

It is becoming more selective.

For compound pharmacies, that creates an opportunity to move away from the noise surrounding GLP-1 products and build a more sustainable specialist peptide proposition around legitimate therapeutic requirements.

The compounders that diversify thoughtfully — rather than chasing every emerging peptide — will be better positioned to adapt as pharmaceutical science and patient needs evolve.

MedicaPharma supports pharmaceutical customers with access to specialist GMP peptide APIs sourced through qualified manufacturing partners and an international network of more than 400 GMP manufacturers.

If you are planning to diversify your peptide offering, exploring a new therapeutic category or looking for a GMP API that is difficult to source, speak with the MedicaPharma team and explore what could be added to your next formulation pipeline.